{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:05:57Z","timestamp":1784293557083,"version":"3.55.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00595-026-03290-4","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:45:13Z","timestamp":1778589913000},"page":"1447-1460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the origins of esophagogastric junction cancer through omics: A focus on the Siewert II subclassification"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-2611","authenticated-orcid":false,"given":"Stamatina","family":"Vogli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros P.","family":"Papadakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios D.","family":"Lianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevas","family":"Gkolfakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis S.","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stratigoula","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gazouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Schizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"3290_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2019.37.4_suppl.40","volume":"37","author":"M Bartel","year":"2019","unstructured":"Bartel M, Brahmbhatt B, Bhurwal A. Incidence of gastroesophageal junction cancer continues to rise: Analysis of Surveillance, Epidemiology, and End Results (SEER) database. J Clin Oncol. 2019;37:40\u201340.","journal-title":"J Clin Oncol"},{"key":"3290_CR2","unstructured":"The Global Landscape of Esophageal Squamous Cell Carcinoma. and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN. 2020."},{"issue":"1","key":"3290_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000519602","volume":"103","author":"N Manabe","year":"2022","unstructured":"Manabe N. Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries. Digestion. 2022;103(1):29\u201336.","journal-title":"Digestion"},{"key":"3290_CR4","doi-asserted-by":"crossref","unstructured":"Bornschein J, Quante M, Jansen M. The complexity of cancer origins at the gastro-oesophageal junction. Best Pr Res Clin Gastroenterol. 2021;50-51(101729).","DOI":"10.1016\/j.bpg.2021.101729"},{"key":"3290_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/gutjnl-2022-327096","volume":"72","author":"M Quante","year":"2023","unstructured":"Quante M. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut. 2023;72:6:1027\u20139.","journal-title":"Gut"},{"key":"3290_CR6","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/gutjnl-2022-327281","volume":"71","author":"K Sugano","year":"2022","unstructured":"Sugano K. Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut. 2022;71:8:1488\u2013514.","journal-title":"Gut"},{"issue":"4","key":"3290_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Esophageal, Junction E, Cancers. Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"key":"3290_CR8","first-page":"1497","volume":"13","author":"M Nishi","year":"1978","unstructured":"Nishi M, Noumura H, Kajisa T, Aiko T, Kaneko Y, Kawaji T. Surgical problem of carcinoma in the esophagogastric junction (in Japanese with English abstract. Stomach Intest. 1978;13:1497\u2013507.","journal-title":"Stomach Intest"},{"key":"3290_CR9","doi-asserted-by":"publisher","unstructured":"Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection, Diseases of the Esophagus [Internet]. Vol. 9. 1996. pp. 173\u2013182,. Available from: https:\/\/doi.org\/10.1093\/dote\/9.3.173","DOI":"10.1093\/dote\/9.3.173"},{"issue":"11","key":"3290_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. J Br Surg. 1998;85(11):1457\u20139.","journal-title":"J Br Surg"},{"key":"3290_CR11","doi-asserted-by":"crossref","unstructured":"Saliba G, Hayami M, Klevebro F, Nilsson M. Surgical Treatment of Siewert Type II Gastroesophageal Junction Cancer: Esophagectomy, Total Gastrectomy or Other Options? Ann Esophagus 2020;3:18.","DOI":"10.21037\/aoe-2020-geja-02"},{"issue":"12","key":"3290_CR12","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1002\/cncr.32066","volume":"125","author":"M Greally","year":"2019","unstructured":"Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer. 2019;125(12):1990\u20132001.","journal-title":"Cancer"},{"key":"3290_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/den.12792","volume":"2","author":"S Ichihara","year":"2017","unstructured":"Ichihara S, Uedo N, Gotoda T. Considering the esophagogastric junction as a \u2018zone\u2019. Dig Endosc. 2017;2:3\u201310.","journal-title":"Dig Endosc"},{"key":"3290_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MCG.0b013e31816b444d","volume":"42","author":"RK Goyal","year":"2008","unstructured":"Goyal RK, Chaudhury A. Physiology of normal esophageal motility. J Clin Gastroenterol. 2008;42:610\u20139.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"3290_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/j.1572-0241.2005.50096.x","volume":"100","author":"RD Odze","year":"2005","unstructured":"Odze RD. Unraveling the mystery of the gastroesophageal junction: a pathologist\u2019s perspective. Am J Gastroenterol. 2005;100(8):1853\u201367.","journal-title":"Am J Gastroenterol"},{"key":"3290_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0016-5107(87)71676-9","volume":"33","author":"SA McClave","year":"1987","unstructured":"McClave SA, Boyce HW, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc. 1987;33:413\u20136.","journal-title":"Gastrointest Endosc"},{"key":"3290_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2559.2005.02088.x","volume":"46","author":"P Chandrasoma","year":"2005","unstructured":"Chandrasoma P. Controversies of the cardiac mucosa and Barrett\u2019s oesophagus. Histopathology. 2005;46:361\u201373.","journal-title":"Histopathology"},{"key":"3290_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/den.13239","volume":"30","author":"H Inoue","year":"2018","unstructured":"Inoue H, Shiwaku H, Iwakiri K. Clinical practice guidelines for peroral endoscopic myotomy. Dig Endosc. 2018;30:563\u201379.","journal-title":"Dig Endosc"},{"key":"3290_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/thx.16.1.36","volume":"16","author":"J Hayward","year":"1961","unstructured":"Hayward J. The lower end of the esophagus. Thorax. 1961;16:36\u201341.","journal-title":"Thorax"},{"key":"3290_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1440-1746.2010.06486.x","volume":"26","author":"Q Huang","year":"2011","unstructured":"Huang Q. Controversies of cardiac glands in the proximal stomach: a critical review. J Gastroenterol Hepatol. 2011;26:450\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"3290_CR21","doi-asserted-by":"crossref","unstructured":"Chandrasoma PT. Fetal \u2018cardiac mucosa\u2019 is not adult cardiac mucosa. Gut. 2003;52(12):1798-1799.","DOI":"10.1136\/gut.52.12.1798"},{"issue":"358\u201363","key":"3290_CR22","first-page":"73","volume":"4","author":"H Zhou","year":"2001","unstructured":"Zhou H, Greco MA, Daum F. Origin of cardiac mucosa: ontogenic consideration. Pediatr Dev Pathol. 2001;4(358\u201363):73.","journal-title":"Pediatr Dev Pathol"},{"key":"3290_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5858\/2003-127-0451-HOGJIF","volume":"127","author":"YS Park","year":"2003","unstructured":"Park YS, Park HJ, Kang GH. Histology of gastroesophageal junction in fetal and pediatric autopsy. Arch Pathol Lab Med. 2003;127:451\u20135.","journal-title":"Arch Pathol Lab Med"},{"key":"3290_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/gut.52.6.791","volume":"52","author":"H G","year":"2003","unstructured":"H G, E P, E N. On the existence and location of cardiac mucosa: an autopsy study in embryos, fetuses, and infants. Gut. 2003;52:791\u20136.","journal-title":"Gut"},{"key":"3290_CR25","doi-asserted-by":"crossref","unstructured":"Prasanna LC. Analysis of the Distribution of Mucins in Adult Human Gastric Mucosa and Its Functional Significance. J Clin Diagn Res. 2016;10(2):AC01-AC4.","DOI":"10.7860\/JCDR\/2016\/12323.7162"},{"key":"3290_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.gastro.2013.06.038","volume":"145","author":"EV Robertson","year":"2013","unstructured":"Robertson EV, Derakhshan MH, Wirz AA. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology. 2013;145:730\u20139.","journal-title":"Gastroenterology"},{"issue":"11","key":"3290_CR27","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1111\/j.1572-0241.1999.01513.x","volume":"94","author":"M Voutilainen","year":"1999","unstructured":"Voutilainen M, F\u00e4rkkil\u00e4 M, Mecklin JP, Juhola M, Sipponen P. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. The Central Finland Endoscopy Study Group. Am J Gastroenterol. 1999;94(11):3175\u201380.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"3290_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825\u201331.","journal-title":"N Engl J Med"},{"key":"3290_CR29","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1001\/jama.1995.03530060048032","volume":"274","author":"WH Chow","year":"1995","unstructured":"Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274:6474\u2013477. Jr.","journal-title":"JAMA"},{"issue":"2","key":"3290_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/gut.2007.131375","volume":"57","author":"DC Whiteman","year":"2008","unstructured":"Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57(2):173\u201380.","journal-title":"Gut"},{"issue":"12","key":"3290_CR31","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1111\/jcmm.13271","volume":"21","author":"DO Prichard","year":"2017","unstructured":"Prichard DO, Byrne AM, Murphy JO. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett\u2019s oesophagus by modulating integrin-\u03b1v trafficking. J Cell Mol Med. 2017;21(12):3612\u201325.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3290_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/gutjnl-2023-329455","volume":"73","author":"H Lu","year":"2023","unstructured":"Lu H, Cao LL, Ballout F. Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma. Gut. 2023;73(1):47\u201362.","journal-title":"Gut"},{"issue":"6","key":"3290_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/ajg.2011.102","volume":"106","author":"B Jovov","year":"2011","unstructured":"Jovov B, Que J, Tobey NA, Djukic Z, Hogan BL, Orlando RC. Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106(6):1039\u201347.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"3290_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/gast.2000.9302","volume":"119","author":"NJ Shaheen","year":"2000","unstructured":"Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett\u2019s esophagus? Gastroenterology. 2000;119(2):333\u20138.","journal-title":"Gastroenterology"},{"issue":"12","key":"3290_CR35","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1111\/j.1572-0241.1999.01602.x","volume":"94","author":"AP Weston","year":"1999","unstructured":"Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett\u2019s multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999;94(12):3413\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"3290_CR36","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/j.1572-0241.2002.05902.x","volume":"97","author":"B Avidan","year":"2002","unstructured":"Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett\u2019s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97(8):1930\u20136.","journal-title":"Am J Gastroenterol"},{"key":"3290_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gutjnl-2015-309220","volume":"65","author":"H Pohl","year":"2016","unstructured":"Pohl H, Pech O, Arash H. Length of Barrett\u2019s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2016;65:196\u2013201.","journal-title":"Gut"},{"issue":"6","key":"3290_CR38","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1053\/j.gastro.2024.03.019","volume":"166","author":"JH Rubenstein","year":"2024","unstructured":"Rubenstein JH, Sawas T, Wani S. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett\u2019s Esophagus and Related Neoplasia. Gastroenterology. 2024;166(6):1020\u201355.","journal-title":"Gastroenterology"},{"issue":"12","key":"3290_CR39","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1055\/a-2176-2440","volume":"55","author":"BLAM Weusten","year":"2023","unstructured":"Weusten BLAM, Bisschops R, Dinis-Ribeiro M. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2023;55(12):1124\u201346.","journal-title":"Endoscopy"},{"issue":"6","key":"3290_CR40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/gutjnl-2023-331557","volume":"73","author":"M di Pietro","year":"2024","unstructured":"di Pietro M, Trudgill NJ, Vasileiou M, Longcroft-Wheaton G, Phillips AW, Gossage J, et al. National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett\u2019s oesophagus and stage I oesophageal adenocarcinoma. Gut. 2024;73(6):897\u2013909.","journal-title":"Gut"},{"issue":"11","key":"3290_CR41","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/00365520701420735","volume":"42","author":"CJ Kelty","year":"2007","unstructured":"Kelty CJ, Gough MD, Wyk Q, Stephenson TJ, Ackroyd R. Barrett\u2019s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol. 2007;42(11):1271\u20134.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"3290_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.humpath.2008.06.008","volume":"40","author":"K Takubo","year":"2009","unstructured":"Takubo K, Aida J, Naomoto Y. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40(1):65\u201374.","journal-title":"Hum Pathol"},{"issue":"4","key":"3290_CR43","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2021.12.271","volume":"162","author":"JA Evans","year":"2022","unstructured":"Evans JA, Carlotti E, Lin ML. Clonal Transitions and Phenotypic Evolution in Barrett\u2019s Esophagus. Gastroenterology. 2022;162(4):1197\u2013209.","journal-title":"Gastroenterology"},{"key":"3290_CR44","doi-asserted-by":"crossref","unstructured":"Gier RA, Hueros RAR, Rong J, DeMarshall M, Karakasheva TA, Muir AB et al. Clonal cell states link Barrett\u2019s esophagus and esophageal adenocarcinoma. bioRxiv [Preprint]. 2023 Feb 6:2023.01.26.525564. doi: 10.1101\/2023.01.26.525564.","DOI":"10.1101\/2023.01.26.525564"},{"issue":"12","key":"3290_CR45","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/gutjnl-2013-306508","volume":"63","author":"DL Lavery","year":"2014","unstructured":"Lavery DL, Nicholson AM, Poulsom R. The stem cell organisation, and the proliferative and gene expression profile of Barrett\u2019s epithelium, replicates pyloric-type gastric glands. Gut. 2014;63(12):1854\u201363.","journal-title":"Gut"},{"key":"3290_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10620-008-0705-0","volume":"55","author":"F Petersson","year":"2010","unstructured":"Petersson F, Franz\u00e9n LE, Borch K. Characterization of the gastric cardia in volunteers from the general population. Type of mucosa, Helicobacter pylori infection, inflammation, mucosal proliferative activity p53 and p21 expression, and relations to gastritis. Dig Sci. 2010;55:46\u201353.","journal-title":"Dig Sci"},{"issue":"9","key":"3290_CR47","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3290_CR48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ijc.22435","volume":"120","author":"D Palli","year":"2007","unstructured":"Palli D, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer. 2007;120(4):859\u201367.","journal-title":"Int J Cancer"},{"key":"3290_CR49","doi-asserted-by":"crossref","unstructured":"Er\u0151ss B, Farkas N, Vincze \u00c1. Helicobacter pylori infection reduces the risk of Barrett\u2019s esophagus: A meta-analysis and systematic review. Helicobacter. 2018;23(4):e12504.","DOI":"10.1111\/hel.12504"},{"issue":"1","key":"3290_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/sj.bjc.6603517","volume":"96","author":"F Kamangar","year":"2007","unstructured":"Kamangar F, Qiao YL, Blaser MJ. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer. 2007;96(1):172\u20136.","journal-title":"Br J Cancer"},{"issue":"11","key":"3290_CR51","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1007\/s10620-010-1351-x","volume":"55","author":"J Bornschein","year":"2010","unstructured":"Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Sci. 2010;55(11):3124\u201331.","journal-title":"Dig Sci"},{"key":"3290_CR52","doi-asserted-by":"crossref","unstructured":"Du YL, Duan RQ, Duan LP. Helicobacter pylori infection is associated with reduced risk of Barrett\u2019s esophagus: a meta-analysis and systematic review. BMC Gastroenterol. 2021;21(1):459.","DOI":"10.1186\/s12876-021-02036-5"},{"issue":"8","key":"3290_CR53","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41395-018-0070-3","volume":"113","author":"Z Wang","year":"2018","unstructured":"Wang Z, Shaheen NJ, Whiteman DC. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett\u2019s Esophagus: An Analysis of the Barrett\u2019s and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018;113(8):1148\u201355.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"3290_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/MCG.0000000000001264","volume":"54","author":"G Usui","year":"2020","unstructured":"Usui G, Sato H, Shinozaki T, Jinno T, Fujibayashi K, Ishii K, et al. Association Between Helicobacter pylori Infection and Short-segment\/Long-segment Barrett\u2019s Esophagus in a Japanese Population: A Large Cross-Sectional Study. J Clin Gastroenterol. 2020;54(5):439\u201344.","journal-title":"J Clin Gastroenterol"},{"issue":"17","key":"3290_CR55","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/jnci\/djq289","volume":"102","author":"MB Cook","year":"2010","unstructured":"Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344\u201353.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"3290_CR56","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/gut.2010.233866","volume":"60","author":"ND Freedman","year":"2011","unstructured":"Freedman ND, Murray LJ, Kamangar F, Abnet CC, Cook MB, Nyren O, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011;60(8):1029\u201337.","journal-title":"Gut"},{"key":"3290_CR57","doi-asserted-by":"crossref","unstructured":"O\u2019Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut. 2012;61(9):1261-8.","DOI":"10.1136\/gutjnl-2011-300551"},{"issue":"5","key":"3290_CR58","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/1055-9965.EPI-05-0860","volume":"15","author":"A Kubo","year":"2006","unstructured":"Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(5):872\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"11","key":"3290_CR59","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/bjc.2017.106","volume":"116","author":"H Freisling","year":"2017","unstructured":"Freisling H, Arnold M, Soerjomataram I. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br J Cancer. 2017;116(11):1486\u201397.","journal-title":"Br J Cancer"},{"issue":"12","key":"3290_CR60","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/00365521.2022.2089859","volume":"57","author":"K Watanabe","year":"2022","unstructured":"Watanabe K, Koizumi S, Shirane K, Tsuda H, Watanabe H, Tsuji T, et al. Diverse contributions of the visceral fat area to the etiology of two distinct subtypes of esophago-gastric junctional adenocarcinoma. Scand J Gastroenterol. 2022;57(12):1463\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"3290_CR61","first-page":"1055","volume":"10","author":"ST Mayne","year":"2001","unstructured":"Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomark Prev. 2001;10(10):1055\u201362.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"3290_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1207\/s15327914nc5402_3","volume":"54","author":"S Bahmanyar","year":"2006","unstructured":"Bahmanyar S, Ye W. Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer. 2006;54(2):171\u20138.","journal-title":"Nutr Cancer"},{"key":"3290_CR63","doi-asserted-by":"publisher","first-page":"1563570","DOI":"10.3389\/fonc.2025.1563570","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wu E, Cheng F, Zhang M, Rou Q, Nuertai Z, et al. Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050. Front Oncol. 2025;15:1563570.","journal-title":"Front Oncol"},{"issue":"12","key":"3290_CR64","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.cgh.2019.11.030","volume":"18","author":"SH Xie","year":"2020","unstructured":"Xie SH, Fang R, Huang M. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett\u2019s Esophagus. Clin Gastroenterol Hepatol. 2020;18(12):2701\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"3290_CR65","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/j.ejca.2010.03.032","volume":"46","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, et al. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: A pooled analysis. Eur J Cancer. 2010;46(11):2067\u201376.","journal-title":"Eur J Cancer"},{"issue":"7636","key":"3290_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169\u201375.","journal-title":"Nature"},{"issue":"1","key":"3290_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000494406","volume":"99","author":"Y Imamura","year":"2019","unstructured":"Imamura Y, Watanabe M, Toihata T, Takamatsu M, Kawachi H, Haraguchi I, et al. Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients. Digestion. 2019;99(1):6\u201313.","journal-title":"Digestion"},{"issue":"26","key":"3290_CR68","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"1171\u20137","key":"3290_CR69","first-page":"43","volume":"23","author":"BA Weinberg","year":"2018","unstructured":"Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL, et al. Immuno-oncology biomarkers for gastric and gastroesophageal junction adenocarcinoma: why PD-L1 testing may not be enough. Oncologist. 2018;23(1171\u20137):43.","journal-title":"Oncologist"},{"key":"3290_CR70","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.2147\/CMAR.S235722","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang S, Zhu C, Cao H, Zhang Z, Zhao E, et al. The association between immune characteristic and clinical pathology in Chinese patients with adenocarcinoma of esophagogastric junction. Cancer Manag Res. 2020;12:3259\u201369.","journal-title":"Cancer Manag Res"},{"key":"3290_CR71","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400\u201316.","journal-title":"Cell"},{"key":"3290_CR72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23\u201332.","journal-title":"JAMA Oncol"},{"key":"3290_CR73","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccell.2018.03.010","volume":"33","author":"Y Liu","year":"2018","unstructured":"Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, SanchezVega F. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell. 2018;33:721\u201335.","journal-title":"Cancer Cell"},{"key":"3290_CR74","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"3290_CR75","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41467-023-36462-8","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yuan L, Xu ZY. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun. 2023;14:778.","journal-title":"Nat Commun"},{"issue":"12","key":"3290_CR76","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/ijc.32384","volume":"145","author":"J Bornschein","year":"2019","unstructured":"Bornschein J, Wernisch L, Secrier M. Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. Int J Cancer. 2019;145(12):3389\u2013401.","journal-title":"Int J Cancer"},{"issue":"10","key":"3290_CR77","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1002\/cam4.1763","volume":"7","author":"M Urabe","year":"2018","unstructured":"Urabe M, Ushiku T, Shinozaki-Ushiku A. Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohort. Cancer Med. 2018;7(10):5145\u201354.","journal-title":"Cancer Med"},{"issue":"6","key":"3290_CR78","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/SLA.0000000000006363","volume":"281","author":"M Nakauchi","year":"2025","unstructured":"Nakauchi M, Walch HS, Nussenzweig S, Carr R, Vos E, Berger MF, et al. Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction: Moving on From the Siewert Classification. Ann Surg. 2025;281(6):989\u201396.","journal-title":"Ann Surg"},{"issue":"11","key":"3290_CR79","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1136\/gutjnl-2020-322707","volume":"70","author":"D Hao","year":"2021","unstructured":"Hao D, He S, Harada K. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021;70(11):2055\u201365.","journal-title":"Gut"},{"key":"3290_CR80","doi-asserted-by":"crossref","unstructured":"Jia PF, Li YR, Wang LY, Lu XR, Guo X. Radiomics in esophagogastric junction cancer: A scoping review of current status and advances. Eur J Radiol. 2024;177:111577.","DOI":"10.1016\/j.ejrad.2024.111577"},{"issue":"31","key":"3290_CR81","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3748\/wjg.v28.i31.4363","volume":"28","author":"KP Du","year":"2022","unstructured":"Du KP, Huang WP, Liu SY. Application of computed tomography-based radiomics in differential diagnosis of adenocarcinoma and squamous cell carcinoma at the esophagogastric junction. World J Gastroenterol. 2022;28(31):4363\u201375.","journal-title":"World J Gastroenterol"},{"key":"3290_CR82","doi-asserted-by":"publisher","first-page":"627947","DOI":"10.3389\/fonc.2021.627947","volume":"11","author":"X Chang","year":"2021","unstructured":"Chang X, Guo X, Li X, Han X, Li X, Liu X, Ren J. Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images. Front Oncol. 2021;11:627947.","journal-title":"Front Oncol"},{"key":"3290_CR83","doi-asserted-by":"publisher","first-page":"707686","DOI":"10.3389\/fonc.2021.707686","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S, Chen Y, Zhang H, Liang Z, Bu J. The Value of Predicting Human Epidermal Growth Factor Receptor 2 Status in Adenocarcinoma of the Esophagogastric Junction on CT-Based Radiomics Nomogram. Front Oncol. 2021;11:707686.","journal-title":"Front Oncol"},{"issue":"12","key":"3290_CR84","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1177\/00031348231183120","volume":"89","author":"N Wada","year":"2023","unstructured":"Wada N, Kurokawa Y, Takahashi T. Accurate Preoperative Evaluation of the Location of Esophagogastric Junction Adenocarcinoma Using Positron Emission Tomography-Computed Tomography. Am Surg. 2023;89(12):6005\u201312.","journal-title":"Am Surg"},{"issue":"1","key":"3290_CR85","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12893-020-00926-1","volume":"20","author":"Y Feng","year":"2020","unstructured":"Feng Y, Jiang Y, Zhao Q, Liu J, Zhang H, Chen Q. Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study. BMC Surg. 2020;20(1):302.","journal-title":"BMC Surg"},{"key":"3290_CR86","doi-asserted-by":"publisher","first-page":"175883592412294","DOI":"10.1177\/17588359241229425","volume":"16","author":"T Jin","year":"2024","unstructured":"Jin T, Li ZD, Chen ZH, He FJ, Chen ZW, Liang PP, et al. Development and validation of a nomogram for Siewert II esophagogastric junction adenocarcinoma: a retrospective analysis. Ther Adv Med Oncol. 2024;16:17588359241229425.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3290_CR87","doi-asserted-by":"publisher","first-page":"zrad138","DOI":"10.1093\/bjsopen\/zrad138","volume":"8","author":"XD Chen","year":"2024","unstructured":"Chen XD, Chen QC, Xu R, Zhao FZ. Therapeutic value of lymph node dissection for Siewert type II and III adenocarcinoma: meta-analysis. BJS Open. 2024;8(1):zrad138.","journal-title":"BJS Open"},{"issue":"3","key":"3290_CR88","doi-asserted-by":"publisher","first-page":"e20240105","DOI":"10.1002\/INMD.20240105","volume":"3","author":"G Pei","year":"2025","unstructured":"Pei G, Liang Z, Gu B, Shi L, Liu Z, Gao S. Molecular subtyping and precision therapy for esophageal cancer. Interdiscip Med. 2025;3(3):e20240105.","journal-title":"Interdiscip Med"},{"issue":"5","key":"3290_CR89","doi-asserted-by":"publisher","first-page":"e257044","DOI":"10.6004\/jnccn.2025.7044","volume":"23","author":"KA Klute","year":"2025","unstructured":"Klute KA, Shah MA. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025;23(5):e257044.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"3290_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325.","journal-title":"Gastric Cancer"},{"issue":"3","key":"3290_CR91","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/00000658-200009000-00007","volume":"232","author":"J R\u00fcdiger Siewert","year":"2000","unstructured":"R\u00fcdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical\/Topographic Classification in 1,002 Consecutive Patients. Ann Surg. 2000;232(3):353\u201361.","journal-title":"Ann Surg"},{"key":"3290_CR92","doi-asserted-by":"publisher","first-page":"813242","DOI":"10.3389\/fonc.2022.813242","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Jiang H, Chen J, Jiang Y, Liu Y, Xu L. Comparison of Efficacy Between Transabdominal and Transthoracic Surgical Approaches for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:813242.","journal-title":"Front Oncol"},{"issue":"5","key":"3290_CR93","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bjs.9456","volume":"101","author":"AR Davies","year":"2014","unstructured":"Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101(5):511\u20137.","journal-title":"Br J Surg"},{"issue":"29","key":"3290_CR94","doi-asserted-by":"publisher","first-page":"10183","DOI":"10.3748\/wjg.v20.i29.10183","volume":"20","author":"MT Wei","year":"2014","unstructured":"Wei MT. Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis. World J Gastroenterol. 2014;20(29):10183.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3290_CR95","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jjco\/hyac019","volume":"52","author":"Y Yanagimoto","year":"2022","unstructured":"Yanagimoto Y, Kurokawa Y, Doki Y, Yoshikawa T, Boku N, Terashima M. Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. Jpn J Clin Oncol. 2022;52(5):417\u201324.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"3290_CR96","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jviscsurg.2025.09.003","volume":"162","author":"DC Ekdal","year":"2025","unstructured":"Ekdal DC, Uprak TK, G\u00fcnal \u00d6, Ye\u011fen \u015eC. The impact of transabdominal and transthoracic surgical approaches on prognosis in gastroesophageal junction tumors. J Visc Surg. 2025;162(6):406\u201315.","journal-title":"J Visc Surg"},{"issue":"1","key":"3290_CR97","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00423-018-1745-3","volume":"404","author":"P Heger","year":"2019","unstructured":"Heger P, Blank S, Goo\u00dfen K, Nienh\u00fcser H, Diener MK, Ulrich A, et al. Thoracoabdominal versus transhiatal surgical approaches for adenocarcinoma of the esophagogastric junction\u2014a systematic review and meta-analysis. Langenbecks Arch Surg. 2019;404(1):103\u201313.","journal-title":"Langenbecks Arch Surg"},{"key":"3290_CR98","doi-asserted-by":"publisher","first-page":"109271","DOI":"10.1016\/j.ejso.2024.109271","volume":"50","author":"V Patsko","year":"2024","unstructured":"Patsko V, Ostapenko Y, Rudskoy A, Lukashenko A. Comparison of left thoracoabdominal approach with Ivor Lewis approach for treatment of esophagogastric junction cancer. Eur J Surg Oncol. 2024;50:109271.","journal-title":"Eur J Surg Oncol"},{"issue":"23","key":"3290_CR99","doi-asserted-by":"publisher","first-page":"450","DOI":"10.21037\/atm.2018.10.66","volume":"6","author":"ZF Yang","year":"2018","unstructured":"Yang ZF, Wu DQ, Wang JJ, Feng XY, Zheng JB, Hu WX, et al. Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? \u2014a single-center retrospective study. Ann Transl Med. 2018;6(23):450\u2013450.","journal-title":"Ann Transl Med"},{"issue":"2","key":"3290_CR100","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"RL Obermannov\u00e1","year":"2025","unstructured":"Obermannov\u00e1 RL, Leong T. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025;10(2):104134.","journal-title":"ESMO Open"},{"issue":"10184","key":"3290_CR101","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet"},{"issue":"22","key":"3290_CR102","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Van Hagen","year":"2012","unstructured":"Van Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med. 2012;366(22):2074\u201384.","journal-title":"N Engl J Med"},{"issue":"7","key":"3290_CR103","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ejso.2015.03.226","volume":"41","author":"F Klevebro","year":"2015","unstructured":"Klevebro F, Johnsen G, Johnson E, Viste A, Myrn\u00e4s T, Szabo E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol EJSO. 2015;41(7):920\u20136.","journal-title":"Eur J Surg Oncol EJSO"},{"issue":"6","key":"3290_CR104","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. J Clin Oncol. 2009;27(6):851\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3290_CR105","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3290_CR106","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705\u201317.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"3290_CR107","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025;393(3):217\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"3290_CR108","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"R Hofheinz","year":"2021","unstructured":"Hofheinz R, Hegewisch-Becker S, Kunzmann V, Thuss\u2010Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5\u2010fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2\u2010positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322\u201331.","journal-title":"Int J Cancer"},{"issue":"19","key":"3290_CR109","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3390\/cancers16193337","volume":"16","author":"F Lordick","year":"2024","unstructured":"Lordick F, Rha SY, Muro K, Yong WP, Lordick Obermannov\u00e1 R. Systemic Therapy of Gastric Cancer\u2014State of the Art and Future Perspectives. Cancers. 2024;16(19):3337.","journal-title":"Cancers"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03290-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-026-03290-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03290-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:02:11Z","timestamp":1784293331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-026-03290-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1007\/s00595-026-03290-4","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review and does not contain any studies with human participants or animals performed by any of the authors. Therefore, ethical approval by an institutional review board and informed consent were not required. The review was conducted in accordance with the ethical standards of the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical Standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}